Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

Topline results were announced from a phase 3 trial evaluating Xyngari™ (formerly DMT310), a novel topical treatment derived ...

AstraZeneca and the Memorial Sloan Kettering Cancer Center (MSK) have tapped digital health tech company IgniteData to ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.

Peeples Cancer Institute at Hamilton Medical Center has expanded access to the latest in cancer research for patients in ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne- - Over 30 million acne patients seek ...